Developer docs
API playgroundTry for free, no card

Search company profiles

FB Dermatology

Full company profile

uuid000fwp3

Namestring
FB Dermatology
Legal namestring
FB DERMATOLOGY s.r.l.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

FB Dermatology s.r.l. is an Italian-headquartered biotech company founded in 2014 as part of the FB Research Group pharmaceutical holding. The company develops and markets proprietary medical devices and consumable gels built around its patented Fluorescent Light Energy (FLE) platform, in which chromophores in a photoconverter gel convert LED light into fluorescent energy that stimulates the skin's own cellular repair mechanisms. Its commercial portfolio is organised into three brands: Kleresca for therapeutic dermatology (acne, rosacea, skin rejuvenation), Lumixa for aesthetic medicine (skin normalising and collagen boosting), and LumiHeal for wound care using Fluorescence Biomodulation, which carries CE mark in Europe. A fourth line, Dermohemp (CBD-based treatments for atopic dermatitis), is listed as forthcoming.

The company sells exclusively through a B2B partner-clinic model rather than direct to consumers. Hardware (LED devices such as the Kleresca Light and LumiHeal Activator) and recurring consumables (photoconverter gels and Light Absorbing Molecule gels) are purchased by dermatology clinics, aesthetic practices, hospitals, and wound care centres that administer treatments to patients. Sales are supported by a field engagement motion targeting clinic decision-makers, a PartnerNet portal for clinic partners, and the FB Academy clinical education programme for healthcare professionals.

FB Dermatology operates across approximately 15 countries spanning Europe (Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Spain, France, the UK, Italy, Luxembourg, the Netherlands, Portugal), the Middle East (Israel), and Oceania (Australia and New Zealand), with named partner clinics including enterprise chains such as Laser Clinics Australia and Laser Clinics New Zealand alongside independent specialty clinics. Pricing is not publicly disclosed and is set by individual partner clinics for end patients. No external venture or private equity funding rounds are disclosed, with capital and strategic direction provided by parent FB Research Group.

Short descriptiontext

FB Dermatology is an Italian biotech company that develops and sells proprietary FLE (Fluorescent Light Energy) medical devices and gel consumables through dermatology, aesthetic, and wound care clinics across Europe, Israel, Australia, and New Zealand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Benedetto Del Tronto, Italy
HQ citystring
San Benedetto Del Tronto
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescent light energy, dermatology treatment systems, photobiomodulation therapy, wound care devices, medical aesthetic systems
Industry4 codes
PRIMARYHLAKACAF
Laser & Energy-Based Dermatology
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYHSALADAJ
LED Light Therapy Treatments
SECONDARYCRABALAF
Professional Skincare & Facial Treatments
Consumer Products & Retail/Beauty & Personal Care/Professional Salon & Spa Products
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Dermatology Treatment Systems
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Kleresca Treatment Systems
TypeHardware Sales
Description

FB Dermatology provides its proprietary FLE technology systems (Kleresca Light device + photoconverter gels) to partner clinics for treating patients with acne, rosacea, and skin rejuvenation. Clinics purchase the treatment systems and consumable gels to administer treatments to patients.

fb-dermatology.com
2LumiHeal Wound Care Products
TypeHardware Sales
Description

Sale of LumiHeal System including LED Activator devices and LAM (Light Absorbing Molecule) topical gel for wound care treatment in hospitals, clinics, and home care settings. Features both hospital/clinic LED Activator and portable handheld version.

fb-dermatology.com
3Lumixa Aesthetic Treatments
TypeHardware Sales
Description

Lumixa phototherapy system and associated gel products for aesthetic conditions including skin normalising and collagen boosting treatments in aesthetic clinics.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1B2B pricing for clinic partners - treatment systems and consumables
ModelOtherBilling cadenceMulti-year contract
Notes

FB Dermatology operates B2B with dermatology clinics and healthcare practices. Individual treatment pricing for patients is set by partner clinics and not disclosed by FB Dermatology.

fb-dermatology.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Kleresca
Description

FLE (Fluorescent Light Energy) treatments for dermatology conditions including acne, rosacea, and skin rejuvenation. Kleresca is the company's primary brand for therapeutic treatments.

fb-dermatology.com
+3 more records
Core offering1 text field

FB Dermatology develops and sells patented Fluorescent Light Energy (FLE) treatment systems for dermatology, aesthetics, and wound care. Its core offerings include the Kleresca brand (LED light device plus photoconverter gel for acne, rosacea, and skin rejuvenation), the Lumixa brand (phototherapy system for aesthetic indications), and the LumiHeal system (LED activator plus Light Absorbing Molecule gel for chronic and acute wounds). Products are sold B2B to licensed clinics and healthcare providers who administer treatments to patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 400% increase in collagen production with Kleresca Skin Rejuvenation
+5 more records
Product overview1 text field

FB Dermatology is a biotech company offering innovative and exclusive patented solutions for tissue regeneration, dermatology conditions, and aesthetic alterations. The product portfolio is organized around FLE (Fluorescent Light Energy) technology, which includes the Kleresca® brand for dermatology conditions (Acne, Rosacea, Skin Rejuvenation) and Lumixa for aesthetic conditions (Skin Normaliser, Collagen Booster). The company also offers LumiHeal® for wound care using Fluorescence Biomodulation, and Dermohemp (CBD-based treatments) is forthcoming. The core Kleresca® FLE platform consists of a patented multi-LED light device and photoconverter gel that converts blue light into fluorescent light energy to stimulate the skin's own repair mechanisms.

Product and service6 records
1Kleresca Acne Treatment
CategoryDermatology Treatment System
Description

FLE-based in-clinic treatment for active acne and acne scarring. Stimulates the skin's own repair mechanisms through fluorescent light energy delivered via LED and photoconverter gel. Designed for dermatology clinics treating moderate to severe acne.

2Kleresca Rosacea Treatment
CategoryDermatology Treatment System
Description

FLE-based treatment reducing pimples, redness, and flushing associated with rosacea. Delivered via Kleresca LED light and photoconverter gel for dermatology clinics.

3Kleresca Skin Rejuvenation
CategoryDermatology Treatment System
Description

Non-destructive FLE treatment stimulating collagen production (up to 400% increase) and improving skin texture, pore size, and fine lines. For dermatology and aesthetic clinics offering rejuvenation procedures.

4Lumixa Skin Normaliser
CategoryAesthetic Phototherapy System
Description

Phototherapy system using FLE to target signs and symptoms of inflammageing. Designed for all skin types to address dehydrated, reactive, or dull skin. For aesthetic clinics.

5Lumixa Collagen Booster
CategoryAesthetic Phototherapy System
Description

Phototherapy system using FLE to target chronoageing or intrinsic ageing. Corrective treatment for ages 35 and above addressing loss of density, fine lines, and open pores. For aesthetic clinics.

6LumiHeal Wound Care System
CategoryWound Care Treatment System
Description

Wound care solution using Fluorescence Biomodulation, delivering fluorescence at cellular level to address all three phases of wound healing (Inflammation, Proliferation, Remodeling). Includes Light Absorbing Molecule (LAM) topical gel activated by LED Activator device (hospital/clinic and portable handheld versions). CE-marked in Europe for chronic wounds including diabetic foot ulcers, venous leg ulcers, and surgical wounds.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1TiME agency
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Web design and marketing agency responsible for FB Dermatology's website design and digital marketing.

fb-dermatology.com
2FB Magazine Contributors
Strategic tierMinorTypeOthers
Description

Patient ambassadors and skin activists who contribute to FB Magazine content, sharing treatment experiences and skin positivity messages.

fb-dermatology.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

FB Dermatology is part of FB Research Group, a pharmaceutical holding company active in several therapeutic areas. Parent company providing strategic direction and resources.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Omnilux is a leading LED photobiomodulation brand offering clinical and at-home devices for acne, skin rejuvenation, and wound healing. Directly comparable to FB Dermatology's FLE technology in mechanism category (LED-based dermatology) and target indications (acne, rejuvenation), making it the closest like-for-like competitor.

2Celluma Light Therapy
TypeDirect peer
Description

Celluma manufactures FDA-cleared LED therapy devices for acne, aging, and pain/wound indications sold to dermatology clinics and medspas. Comparable to FB Dermatology as an LED-based phototherapy device company targeting overlapping indications (acne, rejuvenation) via similar clinic channel.

TypeDirect peer
Description

LightStim produces professional and at-home LED light therapy devices for wrinkles, acne, and pain. Directly overlaps FB Dermatology's Kleresca and LumiHeal in mechanism (LED photobiomodulation) and indication mix, serving the same dermatology and aesthetic clinic segment.

TypeBroad incumbent
Description

Lumenis is a global leader in energy-based medical and aesthetic devices, including IPL and laser systems used by dermatologists for acne, rosacea, and rejuvenation. Comparable to FB Dermatology as a broad energy-based dermatology equipment provider, though Lumenis specializes in laser/IPL rather than fluorescent light energy.

TypeBroad incumbent
Description

Cutera manufactures aesthetic laser and energy-based devices (e.g., AviClear, excel V, enlighten) for dermatology practices and medspas. Comparable to FB Dermatology as an energy-based device company serving dermatology/aesthetic clinics with treatment-system-plus-consumables economics.

TypeBroad incumbent
Description

Alma Lasers, a Sisram Medical company, offers a broad portfolio of aesthetic and surgical energy-based devices including laser, IPL, RF, and ultrasound platforms. Overlaps with FB Dermatology as a multi-platform energy-based aesthetics/dermatology device vendor with global clinic distribution.

7Sciton
TypeBroad incumbent
Description

Sciton produces laser and light-based platforms (BBL, Halo, mJOULE) used by dermatologists and plastic surgeons for skin rejuvenation, pigmentation, and acne. Comparable to FB Dermatology as a clinic-channel energy/light-based dermatology device maker with recurring consumables.

TypeBroad incumbent
Description

Solta Medical (Bausch Health) markets Fraxel, Clear + Brilliant, Thermage, and Liposonix energy-based aesthetic devices. Comparable to FB Dermatology as an established energy/light-based dermatology and aesthetics device vendor with global clinic footprint and consumable model.

TypeDirect peer
Description

Biofrontera is a dermatology specialty company commercializing photodynamic therapy (Ameluz) combined with a proprietary red-light lamp for actinic keratosis and field therapy. Directly comparable to FB Dermatology as a light-plus-topical-agent dermatology treatment system sold to clinics.

TypeBroad incumbent
Description

Galderma is a global dermatology leader offering prescription and aesthetic products (acne, rosacea, skin rejuvenation, wound care) including devices and topicals. Comparable to FB Dermatology as a broad incumbent in the same therapeutic categories (acne, rosacea, skin aging) with both clinic and consumer reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FB Dermatology

Medical Dermatology Treatment Systemsfb-dermatology.com

FB Dermatology is an Italian biotech company that develops and sells proprietary FLE (Fluorescent Light Energy) medical devices and gel consumables through dermatology, aesthetic, and wound care clinics across Europe, Israel, Australia, and New Zealand.

What FB Dermatology does

FB Dermatology s.r.l. is an Italian-headquartered biotech company founded in 2014 as part of the FB Research Group pharmaceutical holding. The company develops and markets proprietary medical devices and consumable gels built around its patented Fluorescent Light Energy (FLE) platform, in which chromophores in a photoconverter gel convert LED light into fluorescent energy that stimulates the skin's own cellular repair mechanisms. Its commercial portfolio is organised into three brands: Kleresca for therapeutic dermatology (acne, rosacea, skin rejuvenation), Lumixa for aesthetic medicine (skin normalising and collagen boosting), and LumiHeal for wound care using Fluorescence Biomodulation, which carries CE mark in Europe. A fourth line, Dermohemp (CBD-based treatments for atopic dermatitis), is listed as forthcoming.

The company sells exclusively through a B2B partner-clinic model rather than direct to consumers. Hardware (LED devices such as the Kleresca Light and LumiHeal Activator) and recurring consumables (photoconverter gels and Light Absorbing Molecule gels) are purchased by dermatology clinics, aesthetic practices, hospitals, and wound care centres that administer treatments to patients. Sales are supported by a field engagement motion targeting clinic decision-makers, a PartnerNet portal for clinic partners, and the FB Academy clinical education programme for healthcare professionals.

FB Dermatology operates across approximately 15 countries spanning Europe (Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Spain, France, the UK, Italy, Luxembourg, the Netherlands, Portugal), the Middle East (Israel), and Oceania (Australia and New Zealand), with named partner clinics including enterprise chains such as Laser Clinics Australia and Laser Clinics New Zealand alongside independent specialty clinics. Pricing is not publicly disclosed and is set by individual partner clinics for end patients. No external venture or private equity funding rounds are disclosed, with capital and strategic direction provided by parent FB Research Group.

FB Dermatology firmographics

Firmographics
Name
FB Dermatology
Legal name
FB DERMATOLOGY s.r.l.
Website
https://fb-dermatology.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
FB Dermatology is an Italian biotech company that develops and sells proprietary FLE (Fluorescent Light Energy) medical devices and gel consumables through dermatology, aesthetic, and wound care clinics across Europe, Israel, Australia, and New Zealand.
Ownership category
akta.pro rank

FB Dermatology industry classification

Industry
Product category
Medical Dermatology Treatment Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKACAF
Laser & Energy-Based Dermatology
SECONDARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
SECONDARYHSALADAJ
LED Light Therapy Treatments
SECONDARYCRABALAF
Professional Skincare & Facial Treatments
Consumer Products & Retail/Beauty & Personal Care/Professional Salon & Spa Products

Keywords

  • Fluorescent light energy
  • Dermatology treatment systems
  • Photobiomodulation therapy
  • Wound care devices
  • Medical aesthetic systems

Where FB Dermatology is headquartered

Location

Headquarters

HQ city
San Benedetto Del Tronto
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

FB Dermatology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Kleresca Treatment Systems: FB Dermatology provides its proprietary FLE technology systems (Kleresca Light device + photoconverter gels) to partner clinics for treating patients with acne, rosacea, and skin rejuvenation. Clinics purchase the treatment systems and consumable gels to administer treatments to patients.
  2. LumiHeal Wound Care Products: Sale of LumiHeal System including LED Activator devices and LAM (Light Absorbing Molecule) topical gel for wound care treatment in hospitals, clinics, and home care settings. Features both hospital/clinic LED Activator and portable handheld version.
  3. Lumixa Aesthetic Treatments: Lumixa phototherapy system and associated gel products for aesthetic conditions including skin normalising and collagen boosting treatments in aesthetic clinics.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pricing for clinic partners - treatment systems and consumables

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

FB Dermatology product offering

Product offering

Core offering

FB Dermatology develops and sells patented Fluorescent Light Energy (FLE) treatment systems for dermatology, aesthetics, and wound care. Its core offerings include the Kleresca brand (LED light device plus photoconverter gel for acne, rosacea, and skin rejuvenation), the Lumixa brand (phototherapy system for aesthetic indications), and the LumiHeal system (LED activator plus Light Absorbing Molecule gel for chronic and acute wounds). Products are sold B2B to licensed clinics and healthcare providers who administer treatments to patients.

Product overview

FB Dermatology is a biotech company offering innovative and exclusive patented solutions for tissue regeneration, dermatology conditions, and aesthetic alterations. The product portfolio is organized around FLE (Fluorescent Light Energy) technology, which includes the Kleresca® brand for dermatology conditions (Acne, Rosacea, Skin Rejuvenation) and Lumixa for aesthetic conditions (Skin Normaliser, Collagen Booster). The company also offers LumiHeal® for wound care using Fluorescence Biomodulation, and Dermohemp (CBD-based treatments) is forthcoming. The core Kleresca® FLE platform consists of a patented multi-LED light device and photoconverter gel that converts blue light into fluorescent light energy to stimulate the skin's own repair mechanisms.

Differentiator

Problem solved

Functional benefit

Brands

  • Kleresca: FLE (Fluorescent Light Energy) treatments for dermatology conditions including acne, rosacea, and skin rejuvenation. Kleresca is the company's primary brand for therapeutic treatments.
  • Lumixa
  • LumiHeal
  • Dermohemp

Products and services

  • Kleresca Acne Treatment FLE-based in-clinic treatment for active acne and acne scarring. Stimulates the skin's own repair mechanisms through fluorescent light energy delivered via LED and photoconverter gel. Designed for dermatology clinics treating moderate to severe acne.
  • Kleresca Rosacea Treatment FLE-based treatment reducing pimples, redness, and flushing associated with rosacea. Delivered via Kleresca LED light and photoconverter gel for dermatology clinics.
  • Kleresca Skin Rejuvenation Non-destructive FLE treatment stimulating collagen production (up to 400% increase) and improving skin texture, pore size, and fine lines. For dermatology and aesthetic clinics offering rejuvenation procedures.
  • Lumixa Skin Normaliser Phototherapy system using FLE to target signs and symptoms of inflammageing. Designed for all skin types to address dehydrated, reactive, or dull skin. For aesthetic clinics.
  • Lumixa Collagen Booster Phototherapy system using FLE to target chronoageing or intrinsic ageing. Corrective treatment for ages 35 and above addressing loss of density, fine lines, and open pores. For aesthetic clinics.
  • LumiHeal Wound Care System Wound care solution using Fluorescence Biomodulation, delivering fluorescence at cellular level to address all three phases of wound healing (Inflammation, Proliferation, Remodeling). Includes Light Absorbing Molecule (LAM) topical gel activated by LED Activator device (hospital/clinic and portable handheld versions). CE-marked in Europe for chronic wounds including diabetic foot ulcers, venous leg ulcers, and surgical wounds.

Quantifiable outcome

  • Up to 400% increase in collagen production with Kleresca Skin Rejuvenation
  • +5 more outcomes

Companies that use FB Dermatology

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

FB Dermatology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

FB Dermatology partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • TiME agencyminorImplementation/ SI/ Consulting PartnerWeb design and marketing agency responsible for FB Dermatology's website design and digital marketing.
  • FB Magazine ContributorsminorOthersPatient ambassadors and skin activists who contribute to FB Magazine content, sharing treatment experiences and skin positivity messages.
  • FB Research GroupcoreStrategic or Co-development PartnerFB Dermatology is part of FB Research Group, a pharmaceutical holding company active in several therapeutic areas. Parent company providing strategic direction and resources.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

FB Dermatology competitors and assessment

Company assessment

Direct peers

  • Omnilux: Omnilux is a leading LED photobiomodulation brand offering clinical and at-home devices for acne, skin rejuvenation, and wound healing. Directly comparable to FB Dermatology's FLE technology in mechanism category (LED-based dermatology) and target indications (acne, rejuvenation), making it the closest like-for-like competitor.
  • Celluma Light Therapy: Celluma manufactures FDA-cleared LED therapy devices for acne, aging, and pain/wound indications sold to dermatology clinics and medspas. Comparable to FB Dermatology as an LED-based phototherapy device company targeting overlapping indications (acne, rejuvenation) via similar clinic channel.
  • LightStim: LightStim produces professional and at-home LED light therapy devices for wrinkles, acne, and pain. Directly overlaps FB Dermatology's Kleresca and LumiHeal in mechanism (LED photobiomodulation) and indication mix, serving the same dermatology and aesthetic clinic segment.
  • Biofrontera: Biofrontera is a dermatology specialty company commercializing photodynamic therapy (Ameluz) combined with a proprietary red-light lamp for actinic keratosis and field therapy. Directly comparable to FB Dermatology as a light-plus-topical-agent dermatology treatment system sold to clinics.

Broad incumbents

  • Lumenis: Lumenis is a global leader in energy-based medical and aesthetic devices, including IPL and laser systems used by dermatologists for acne, rosacea, and rejuvenation. Comparable to FB Dermatology as a broad energy-based dermatology equipment provider, though Lumenis specializes in laser/IPL rather than fluorescent light energy.
  • Cutera: Cutera manufactures aesthetic laser and energy-based devices (e.g., AviClear, excel V, enlighten) for dermatology practices and medspas. Comparable to FB Dermatology as an energy-based device company serving dermatology/aesthetic clinics with treatment-system-plus-consumables economics.
  • Alma Lasers: Alma Lasers, a Sisram Medical company, offers a broad portfolio of aesthetic and surgical energy-based devices including laser, IPL, RF, and ultrasound platforms. Overlaps with FB Dermatology as a multi-platform energy-based aesthetics/dermatology device vendor with global clinic distribution.
  • Sciton: Sciton produces laser and light-based platforms (BBL, Halo, mJOULE) used by dermatologists and plastic surgeons for skin rejuvenation, pigmentation, and acne. Comparable to FB Dermatology as a clinic-channel energy/light-based dermatology device maker with recurring consumables.
  • Solta Medical: Solta Medical (Bausch Health) markets Fraxel, Clear + Brilliant, Thermage, and Liposonix energy-based aesthetic devices. Comparable to FB Dermatology as an established energy/light-based dermatology and aesthetics device vendor with global clinic footprint and consumable model.
  • Galderma: Galderma is a global dermatology leader offering prescription and aesthetic products (acne, rosacea, skin rejuvenation, wound care) including devices and topicals. Comparable to FB Dermatology as a broad incumbent in the same therapeutic categories (acne, rosacea, skin aging) with both clinic and consumer reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

FB Dermatology social profiles

Digital presence

FB Dermatology compliance and trust

Trust signal

Compliance1 record

FB Dermatology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FB Dermatology leadership team

Management profile

Number of profiles

FB Dermatology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FB Dermatology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FB Dermatology

What does FB Dermatology do?

FB Dermatology develops and sells patented Fluorescent Light Energy (FLE) treatment systems for dermatology, aesthetics, and wound care. Its core offerings include the Kleresca brand (LED light device plus photoconverter gel for acne, rosacea, and skin rejuvenation), the Lumixa brand (phototherapy system for aesthetic indications), and the LumiHeal system (LED activator plus Light Absorbing Molecule gel for chronic and acute wounds). Products are sold B2B to licensed clinics and healthcare providers who administer treatments to patients.

Is FB Dermatology a public or private company?

FB Dermatology is a private company. It is classified as corporate owned and is currently operating.

When was FB Dermatology founded?

FB Dermatology was founded in 2014. It employs 11 to 50 people.

Where is FB Dermatology based?

FB Dermatology is headquartered in San Benedetto Del Tronto, Italy, in the Europe region.

How does FB Dermatology make money?

Three revenue lines are on record. Kleresca Treatment Systems are the primary driver. The others are lumiHeal Wound Care Products and lumixa Aesthetic Treatments.

Who are FB Dermatology's main competitors?

Direct peers on record are Omnilux, Celluma Light Therapy, LightStim and Biofrontera. Broad incumbents are Lumenis, Cutera, Alma Lasers, Sciton, Solta Medical and Galderma.

Does FB Dermatology have an API?

No public API is recorded for FB Dermatology.

What industry is FB Dermatology in?

FB Dermatology's product category is Medical Dermatology Treatment Systems. Its primary akta.pro industry code is HLAKACAF, Laser & Energy-Based Dermatology, with a secondary code of CRABAKAI, Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB DermatologyKane Biotech will host an investor webinar on January 23, 2025, to outline its 2025 plans, including the acquisition of FB Dermatology. The company also announced a six-month marketing services agreement with Outside The Box Capital, which received $100,000.TipranksKane Biotech Expands with FB Dermatology AcquisitionKane Biotech plans to acquire FB Dermatology to expand its wound care and dermatology portfolio and global commercial reach. The deal is expected to accelerate commercialization of Kane's products in international markets using FB Dermatology's sales networks, aiming to maximize shareholder value and strengthen Kane's market position.BenzingaKane Biotech Announces Agreement to Acquire FB Dermatology - Kane Biotech (OTC:KNBIF)Kane Biotech Inc. has entered into a binding term sheet to acquire FB Dermatology S.R.L., an Italian biotechnology company with operations in Italy, Australia, and New Zealand. The acquisition involves an aggregate purchase price of approximately $2.5 million in cash and equity, aimed at accelerating the commercialization of Kane Biotech's wound care products in international markets.PR NewswireKlox Technologies Inc. Announces Completion of the Acquisition of FB DermatologyKlox Technologies Inc. announced it has completed the acquisition of FB Dermatology, a specialized dermatology company commercializing the Kleresca® product line for acne, rosacea, and skin rejuvenation treatments. The transaction unifies both companies' teams and combines their product portfolios, including Klox's LumiHeal™ offering, creating a consolidated leader in regenerative medicine utilizing fluorescent light energy technologies. Kleresca® products are currently commercially available in select markets across Europe and Australia.